目的观察替吉奥单药与替吉奥联合顺铂治疗老年进展期胃癌的近期疗效、临床受益率和毒副反应。方法 48例老年进展期胃癌患者被随机分入观察组和对照组。观察组24例,患者接受替吉奥胶囊单药口服,连用28 d,停药14 d后再进行下1周期治疗,共完成4周期化疗;对照组24例,采用替吉奥胶囊口服,连用14 d,服药第1～3天给予顺铂静滴化疗,休息7 d后再进行下1周期治疗,用药4周期后评价疗效。结果观察组总有效率为45.8%,临床受益率为91.7%;对照组总有效率为54.2%,临床受益率为66.7%。两组比较近期疗效差异无统计学意义(P>0.05),临床受益率、毒副反应的发生率两组间差异有统计学意义(P<0.05)。结论替吉奥胶囊单药口服治疗老年进展期胃癌可取得较好的近期疗效,可明显提高患者生存质量,耐受性良好。 Objective To observe the short-term curative effect, clinical benefit rate and toxic and side effects of the treatment of gefitinib monotherapy and tegaserod combined with cisplatin in the treatment of advanced gastric cancer. Methods 48 cases of advanced gastric cancer patients were randomly divided into observation group and control group. In the observation group of 24 cases, the patients received oral administration of Tegi capsule alone for 28 days. After 14 days of discontinuation, they were treated with the next cycle. Four cycles of chemotherapy were completed. In the control group, 24 cases were treated with Tegi capsule, On the 14th day, cisplatin was intravenously administered on the 1st to 3rd day after taking the medicine. After the rest for 7 days, the next cycle of treatment was carried out. After 4 cycles, the curative effect was evaluated. Results The total effective rate was 45.8% in the observation group, the clinical benefit rate was 91.7%; the control group, the total effective rate was 54.2%, the clinical benefit rate was 66.7%. There was no significant difference between the two groups in the short term curative effect (P> 0.05). There was significant difference between the two groups in clinical benefit rate and incidence of toxic and side effects (P <0.05). Conclusion Treating geegoc capsule single oral oral administration of advanced gastric cancer can achieve better short-term curative effect, which can significantly improve the quality of life of patients and is well tolerated.